Elevated interleukin-6 and severe COVID-19 : A meta-analysis
| Errataetall: |
CommentOn: J Med Virol. 2020 Jul;92(7):814-818. - PMID 32253759 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Journal of medical virology - 92(2020), 11 vom: 28. Nov., Seite 2283-2285 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aziz, Muhammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 18.12.2020 Date Revised 16.07.2022 published: Print-Electronic CommentOn: J Med Virol. 2020 Jul;92(7):814-818. - PMID 32253759 Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.25948 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309274265 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309274265 | ||
| 003 | DE-627 | ||
| 005 | 20231225133540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.25948 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1030.xml |
| 035 | |a (DE-627)NLM309274265 | ||
| 035 | |a (NLM)32343429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aziz, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elevated interleukin-6 and severe COVID-19 |b A meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2020 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Med Virol. 2020 Jul;92(7):814-818. - PMID 32253759 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Fatima, Rawish |e verfasserin |4 aut | |
| 700 | 1 | |a Assaly, Ragheb |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 92(2020), 11 vom: 28. Nov., Seite 2283-2285 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2020 |g number:11 |g day:28 |g month:11 |g pages:2283-2285 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.25948 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2020 |e 11 |b 28 |c 11 |h 2283-2285 | ||